Journal article
Development of macrocycle kinase inhibitors for ALK2 using Fibrodysplasia ossificans progressiva‐derived endothelial cells
- Abstract:
-
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous mutations in the Activin A type I receptor (ACVR1), that encodes the bone morphogenetic protein (BMP) type I receptor ALK2. These mutations enable ALK2 to induce downstream signaling in response to Activins, thereby turning them into bone inducing agents. To date there is no cure for FOP. The further development of FOP patie...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- JBMR Plus Journal website
- Volume:
- 3
- Issue:
- 11
- Pages:
- e10230
- Publication date:
- 2019-10-07
- Acceptance date:
- 2019-08-06
- DOI:
- EISSN:
-
2473-4039
Item Description
- Keywords:
- Pubs id:
-
pubs:1039497
- UUID:
-
uuid:3f89f36a-ce63-4508-940b-02ce522b0264
- Local pid:
- pubs:1039497
- Source identifiers:
-
1039497
- Deposit date:
- 2019-08-07
Terms of use
- Copyright holder:
- Sánchez‐Duffhues et al
- Copyright date:
- 2019
- Notes:
- © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record